Mark Glickman has resigned as chief commercial officer of Aralez Pharmaceuticals Inc. to pursue other opportunities.
Glickman's resignation will be effective as of March 30.
Discover more about S&P Global’s offerings
Aralez Pharmaceuticals chief commercial officer resigns
Essential IR Insights Newsletter Fall - 2023
A Corporation Clearly Pinpoints Activist Investor Activity
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Mark Glickman has resigned as chief commercial officer of Aralez Pharmaceuticals Inc. to pursue other opportunities.
Glickman's resignation will be effective as of March 30.